Myocarditis Heart Damage in 1 Out of 35 Covid Vaccinations | NextBigFuture.com
A new study of 777 people found that 22 had markers that indicated the mRNA-1273 covid vaccine caused myocardial injury in 1 out of 35 people. This is about thousand times more than prior estimates of myocardial injury. It would mean if 1.8 billion people in the world had covid vaccinations and boosters then 50 million would have had myocardial injury. This would usually be mild and transitory but if those people had strenuous exercise during this period they could trigger heart attacks. This would mean if 280 million people in the USA had covid vaccinations and boosters then you would expect about 8 million to have experienced myocardial injury from the vaccination.
Vaccination is a medical agent that causes your immune system to act against a target disease. This study indicates a side effect of activating your immune system to fight covid where the immune system temporarily attacks heart muscle in 1 out of 35 people (if the study is correct).
The Cleveland Clinic provides statistics related to regular myocarditis. The situation is likely different for vaccination triggered myocarditis.
Many people can live for years without problems after myocarditis treatment. Other people may need to keep taking medication. There’s a small risk of myocarditis happening again.
For some people, myocarditis can lead to dilated cardiomyopathy and they may need a heart transplant. Almost 20% of sudden deaths in young people have a connection to myocarditis.
The survival rate for myocarditis is 80% one year after having it and 50% five years later.
John Hopkins discusses regular myocarditis.
Myocarditis occurs when the heart muscle becomes inflamed. When your heart muscle is inflamed, it can affect your heart’s electrical system. This can cause arrhythmia, or a rapid or abnormal heartbeat. Myocarditis can cause the heart muscle to weaken and can lead to cardiomyopathy. Myocarditis occurs when the heart muscle (myocardium) becomes inflamed. Inflammation occurs when your body’s immune system responds to infections, for example. Myocarditis can be caused by viral infections or more systemic inflammatory conditions such as autoimmune disorders. In severe cases of myocarditis, the heart muscle weakens and cannot pump blood effectively to other parts of your body.
Here is the link to the study: Sex-specific differences in myocardial injury incidence after COVID-19 mRNA-1273 Booster Vaccination.
Among 777 participants, median age 37 years, 69.5% women, 40 participants had elevated hs-cTnT concentration on day 3 and mRNA-1273 vaccine-associated myocardial injury was adjudicated in 22 participants. Twenty cases occurred in women, two in men. Hs-cTnT-elevations were mild and only temporary. No patient had ECG-changes, and none developed major adverse cardiac events within 30 days.
Patients in this study were warned not to exercise for 30 days after vaccination if myocardial injury markers were detected.
Ten to twenty times the number of people who would show any symptoms that would indicate possible myocardial injury from covid vaccination. Not all people with chest pain would get flagged as possibly having myocardial injury.
The CDC still recommends everyone ages 6 months and older get vaccinated as soon as possible to protect against COVID-19 and its potentially severe complications. Myocarditis is inflammation of the heart muscle, and pericarditis is inflammation of the lining outside the heart; myopericarditis is present when both myocarditis and pericarditis occur at the same time.
John Campbell calls this “off the charts” adverse reaction. He says people need to be told about this issue and the frequency of it before vaccine boosters to have informed consent. There needs to be monitoring for everyone for elevated hs-cTnT concentration. Those with elevated markers must be told not to exercise for 30 days and be monitored for heart problems.
Natacha Buergin1*,
Pedro Lopez-Ayala1*,
Julia R. Hirsiger2,
Philip Mueller1,
Daniela Median1,
Noemi Glarner1,
Klara Rumora1,
Timon Herrmann1,
Luca Koechlin1,
Philip Haaf1,
Katharina Rentsch3,
Manuel Battegay4,
Florian Banderet5,6,
Christoph T. Berger2, 7,
ChristianMueller1
1Department of Cardiology and Cardiovascular Research Institute Basel (CRIB), University Hospital Basel, University of Basel, Basel;
2Department of Biomedicine, Translational Immunology, University of Basel, Basel;
3Department of Laboratory Medicine, University Hospital Basel, University of Basel, Basel;
4Department of Infectious diseases & Hospital Epidemiology , University Hospital Basel, University of Basel, Basel;
5Department of Internal Medicine, Medical Outpatient Unit, University Hospital Basel, Basel;
6Employee health service, University Hospital Basel, Basel Switzerland,
7University Center for Immunology, University Hospital Basel, Basel
Prof. Christian Mueller, Cardiovascular Research Institute Basel (CRIB) and Department of Cardiology, University Hospital Basel, Petersgraben 4, CH-4031 Basel, Switzerland.
Other Post-Vaccine Myocarditis Studies
Prof Iwasaki: Myocarditis risk depends on the age and sex of the vaccine recipient. It is most common in younger males—adolescents or young adults. The highest risk group is males between 12 and 17 years of age. And in that highest risk group, the myocarditis risk after the second dose, which is the highest, is 35.9 per 100,000 people. In comparison, the risk post-infection in that same group is 64.9 per 100,000.
Professor Iwasaki, you have said you are “a little relieved” to have found myocarditis cases to be inflammation-induced. Why is that?
Iwasaki: Autoimmune-related myocarditis is more difficult to treat. It would be more chronic, because once you trigger an autoimmune response, it’s very difficult to shut it down. For example, if you develop auto antibodies against components of the cardiac muscle, it’s difficult to get rid of those B cells that are secreting those antibodies, creating chronic disease. Whereas inflammation-induced myocarditis is more transient—we actually found that inflammation as well as the immune cell types go back to normal after patients recover. So we know that it’s a resolving kind of myocarditis. We don’t want to diminish patients’ suffering, but this kind of myocarditis is better than other types.
Nextbigfuture NOTE: It is not clear that the 36 people getting post-vaccine myocarditis are the same people who would get post-covid infection myocarditis. Also, why can’t we get a covid vaccine that has no myocarditis risk? In the meantime, people need to be fully informed, warned and closely monitored for this substantial post-vaccination risk.
Vaccine Vs Covid
A commenter was comparing the risk of myocarditis from the vaccine with myocarditis from Covid. However, the low number of cases (under 40,000 per week) means about 2 million people in the US might get Covid in a year.
This means less than 1% of the population would get Covid in a year. Vaccine protection fades over time. An annual vaccine that is 1/7th the risk of covid where 50% of the population was vaccinated would mean increasing the risk of myocarditis by 7 times with vaccination.
Younger people are less vulnerable to covid but more vulnerable to myocarditis. This would mean that it would mean the odds are better for most young people (under 40 or 50) to accept the no longer pandemic covid risk rather than the clear excessive amounts of adverse risks from a flawed vaccine.
This does get down to personal risks of covid exposure, vulnerability to the current covid strain and personal risk to the particular covid vaccine. Widely distributed vaccines should not have this level of adverse reaction.
Brian Wang is a Futurist Thought Leader and a popular Science blogger with 1 million readers per month. His blog Nextbigfuture.com is ranked #1 Science News Blog. It covers many disruptive technology and trends including Space, Robotics, Artificial Intelligence, Medicine, Anti-aging Biotechnology, and Nanotechnology.
Known for identifying cutting edge technologies, he is currently a Co-Founder of a startup and fundraiser for high potential early-stage companies. He is the Head of Research for Allocations for deep technology investments and an Angel Investor at Space Angels.
A frequent speaker at corporations, he has been a TEDx speaker, a Singularity University speaker and guest at numerous interviews for radio and podcasts. He is open to public speaking and advising engagements.